{"prompt": "Make reference to the context given to assess the scenario. If you do not know the answer. just say that \"I don't know\", don't try to make up an answer.\nYou are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step\n\nANALYSE the given patient profile based on given query based on the following criteria:\n- Freshly treated patient or patient under maintenance\n- Prior response to Infliximab\n- Prior failure to Anti-TNF agents\n- Prior failure to Vedolizumab\n- Age\n- Pregnancy\n- Extraintestinale manifestations\n- Pouchitis\n\nFINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n\nsummaries\n\nThe output should be formatted as a JSON instance that conforms to the JSON schema below.\n\nAs an example, for the schema {\"properties\": {\"foo\": {\"title\": \"Foo\", \"description\": \"a list of strings\", \"type\": \"array\", \"items\": {\"type\": \"string\"}}}, \"required\": [\"foo\"]}}\nthe object {\"foo\": [\"bar\", \"baz\"]} is a well-formatted instance of the schema. The object {\"properties\": {\"foo\": [\"bar\", \"baz\"]}} is not well-formatted.\n\nHere is the output schema:\n```\n{\"properties\": {\"drug_name\": {\"title\": \"Drug Name\", \"description\": \"Name of the drug\", \"type\": \"string\"}, \"advantages\": {\"title\": \"Advantages\", \"description\": \"Advantages of the drug \", \"type\": \"string\"}, \"disadvantages\": {\"title\": \"Disadvantages\", \"description\": \"Disadvantages of the drug\", \"type\": \"string\"}}, \"required\": [\"drug_name\", \"advantages\", \"disadvantages\"]}\n```\n\nQuestion: question\nAnswer:\n", "test_cases": [{"question": "40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations\n", "answer": "I don't know.", "sources": [{"title": "", "filename": "otad009.pdf", "page": 14, "text": "moderately to severely active UC.\nSupplementary Data\nSupplementary data is available at Crohn\u2019s and Colitis 360 \nonline.\nFunding\nThis work was supported by AbbVie Inc., who funded this \nstudy and participated in the study design, research, analy-\nsis, data collection, interpretation of data, reviewing, and ap-\nproval of the publication. All authors had access to relevant \ndata and participated in the drafting, review, and approval of \nthis publication. No honoraria or payments were made for \nauthorship. Medicus Economics LLC has received funding \nfrom AbbVie Inc. for technical writing assistance.\nAuthors\u2019 Contributions\nRemo Panaccione: Writing\u2014review and editing (equal), Eric \nB. Collins: Methodology (supporting), formal analysis (e-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "clinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 5, "text": "Table 1. Overall, the median average age of patients was\n41 years (interquartile range, 40\u201342 y), and 60%\n(interquartile range, 56%\u201363%) were men. The median\ndisease duration was 6.7 years (interquartile range,\n6.0\u20137.8 y), and 49% (interquartile range, 46%\u201355%) of\npatients had extensive colitis. A median of 40% (inter-\nquartile range, 30%\u201350%) of patients were treated with\nconcomitant immunomodulators, and 51% (interquartile\nrange, 45%\u201357%) were on corticosteroids at baseline.\nPatients across all trials and treatment arms were com-\nparable in terms of baseline prognostic variables, inclu-\nsion/exclusion\ncriteria,\nand\nco-interventions.\nAll\noutcomes were assessed uniformly based on the stan-"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on"}]}, {"question": "70 year old female with newly diagnosed severe UC\n", "answer": "I don't know.", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "clinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "Introduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited."}]}, {"question": "35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance\n", "answer": "[\n  {\n    \"drug_name\": \"Vedolizumab\",\n    \"advantages\": \"Vedolizumab is ranked highly for inducing endoscopic improvement in biologic-na\u00efve patients with moderate\u2013severe ulcerative colitis. It can be a good option for patients who have had prior exposure to TNF antagonists like infliximab.\",\n    \"disadvantages\": \"The patient may not respond to Vedolizumab as well if they have had prior exposure to TNF antagonists. The effectiveness of the drug may also vary from patient to patient.\"\n  },\n  {\n    \"drug_name\": \"Ustekinumab\",\n    \"advantages\": \"Ustekinumab can be used if the patient has prior exposure to TNF antagonists. It is also effective in inducing endoscopic improvement in patients with moderate to severe ulcerative colitis.\",\n    \"disadvantages\": \"The effectiveness of Ustekinumab can vary from patient to patient. It may not be as effective as other drugs like infliximab or vedolizumab in inducing endoscopic improvement.\"\n  }\n]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "clinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "needed to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "colitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;\nand (4) outcome: induction of clinical remission (Mayo\nClinic score of \ufffd2 with no individual subscore of >1)"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7, "text": "mates (OR, 1.32; 95% CI, 0.73\u20132.37) (Table 2). Overall,\nin\ufb02iximab (SUCRA, 0.95) and vedolizumab (SUCRA, 0.76)\nwere ranked highest for inducing endoscopic improve-\nment in biologic-na\u00efve patients with moderate\u2013severe\nulcerative colitis (Figure 2A). With an estimated pla-\ncebo rate of achieving endoscopic improvement of 30%\nin induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior"}]}, {"question": "60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure\n", "answer": "\"I don't know\"", "sources": [{"title": "", "filename": "otad009.pdf", "page": 14, "text": "moderately to severely active UC.\nSupplementary Data\nSupplementary data is available at Crohn\u2019s and Colitis 360 \nonline.\nFunding\nThis work was supported by AbbVie Inc., who funded this \nstudy and participated in the study design, research, analy-\nsis, data collection, interpretation of data, reviewing, and ap-\nproval of the publication. All authors had access to relevant \ndata and participated in the drafting, review, and approval of \nthis publication. No honoraria or payments were made for \nauthorship. Medicus Economics LLC has received funding \nfrom AbbVie Inc. for technical writing assistance.\nAuthors\u2019 Contributions\nRemo Panaccione: Writing\u2014review and editing (equal), Eric \nB. Collins: Methodology (supporting), formal analysis (e-"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "clinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "Introduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited."}]}, {"question": "38 year old female with newly diagnosed moderate UC and psoriasis\n", "answer": "I don't know.", "sources": [{"title": "", "filename": "otad009.pdf", "page": 1, "text": "development for moderately to severely active UC. Most \nrecently, Lasa et al11 and Burr et al12 each conducted and \npublished a systematic literature review (SLR) and frequentist \nnetwork meta-analysis (NMA) on the efficacy and safety of \nbiologics and SMDs for patients with moderately to severely \nUC. Both studies assessed all outcomes after induction (6\u201314 \nweeks); Lasa et al11 additionally assessed efficacy after main-\ntenance (26\u201366 weeks) separately for treat-through (TT) and \nre-randomized responders (RR) randomized clinical trials \n(RCTs). Both studies also assessed all outcomes in overall \npopulations, as well as induction efficacy outcomes by prior \nbiologic exposure, though UPA was excluded from subgroup"}, {"title": "", "filename": "otad009.pdf", "page": 14, "text": "moderately to severely active UC.\nSupplementary Data\nSupplementary data is available at Crohn\u2019s and Colitis 360 \nonline.\nFunding\nThis work was supported by AbbVie Inc., who funded this \nstudy and participated in the study design, research, analy-\nsis, data collection, interpretation of data, reviewing, and ap-\nproval of the publication. All authors had access to relevant \ndata and participated in the drafting, review, and approval of \nthis publication. No honoraria or payments were made for \nauthorship. Medicus Economics LLC has received funding \nfrom AbbVie Inc. for technical writing assistance.\nAuthors\u2019 Contributions\nRemo Panaccione: Writing\u2014review and editing (equal), Eric \nB. Collins: Methodology (supporting), formal analysis (e-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 5, "text": "Table 1. Overall, the median average age of patients was\n41 years (interquartile range, 40\u201342 y), and 60%\n(interquartile range, 56%\u201363%) were men. The median\ndisease duration was 6.7 years (interquartile range,\n6.0\u20137.8 y), and 49% (interquartile range, 46%\u201355%) of\npatients had extensive colitis. A median of 40% (inter-\nquartile range, 30%\u201350%) of patients were treated with\nconcomitant immunomodulators, and 51% (interquartile\nrange, 45%\u201357%) were on corticosteroids at baseline.\nPatients across all trials and treatment arms were com-\nparable in terms of baseline prognostic variables, inclu-\nsion/exclusion\ncriteria,\nand\nco-interventions.\nAll\noutcomes were assessed uniformly based on the stan-"}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and"}]}, {"question": "25 year old pregnant woman with severe distal ulcerative colitis\n", "answer": "I don't know", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "Introduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited."}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on"}, {"title": "", "filename": "otad009.pdf", "page": 11, "text": "Downloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}]}, {"question": "56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis\n", "answer": "I don't know.", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "Introduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "clinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 5, "text": "Table 1. Overall, the median average age of patients was\n41 years (interquartile range, 40\u201342 y), and 60%\n(interquartile range, 56%\u201363%) were men. The median\ndisease duration was 6.7 years (interquartile range,\n6.0\u20137.8 y), and 49% (interquartile range, 46%\u201355%) of\npatients had extensive colitis. A median of 40% (inter-\nquartile range, 30%\u201350%) of patients were treated with\nconcomitant immunomodulators, and 51% (interquartile\nrange, 45%\u201357%) were on corticosteroids at baseline.\nPatients across all trials and treatment arms were com-\nparable in terms of baseline prognostic variables, inclu-\nsion/exclusion\ncriteria,\nand\nco-interventions.\nAll\noutcomes were assessed uniformly based on the stan-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "patients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials"}]}, {"question": "38 year old man with severe ulcerative colitis and has lost response to vedolizumab\n", "answer": "[\n  {\n    \"drug_name\": \"Infliximab\",\n    \"advantages\": \"Infliximab is recommended as first-line therapy for moderate to severe ulcerative colitis. It has been proven effective in clinical trials and is widely used in practice.\",\n    \"disadvantages\": \"Infliximab is an immunosuppressive drug, which means it can increase the risk of infections. It can also cause allergic reactions in some patients.\"\n  },\n  {\n    \"drug_name\": \"Tofacitinib\",\n    \"advantages\": \"Tofacitinib is recommended for patients who have had prior exposure to TNF antagonists. It is a small molecule drug that can be taken orally, which may be more convenient for some patients.\",\n    \"disadvantages\": \"Tofacitinib can increase the risk of serious infections, malignancies, and thrombosis. It may also cause elevated cholesterol levels and liver enzyme elevations.\"\n  }\n]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "needed to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "colitis. Vedolizumab was the best performing agent for safety outcomes. With the paucity of direct comparisons in the \npublished literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11, "text": "3.\nVester-Andersen MK, Prosberg MV, Jess T, et al. Disease\ncourse and surgery rates in in\ufb02ammatory bowel disease: a\npopulation-based, 7-year follow-up study in the era of immu-\nnomodulating therapy. Am J Gastroenterol 2014;109:705\u2013714.\n4.\nBonovas S, Lytras T, Nikolopoulos G, et al. Systematic review\nwith network meta-analysis: comparative assessment of tofa-\ncitinib and biological therapies for moderate-to-severe ulcera-\ntive colitis. Aliment Pharmacol Ther 2018;47:454\u2013465.\n5.\nSingh S, Fumery M, Sandborn WJ, et al. Systematic review with\nnetwork meta-analysis: \ufb01rst- and second-line pharmacotherapy\nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther\n2018;47:162\u2013175.\n6.\nSands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "Cheng, D., Cushing, K.C., Cai, T., Ananthakrishnan, A.N., 2021. Safety and ef\ufb01cacy of\ntumor necrosis factor antagonists in older patients with ulcerative colitis: patient-\nlevel pooled analysis of data from randomized trials. Clin. Gastroenterol. Hepatol. 19\n(5), 939\u2013946.\nChristensen, B., Micic, D., Gibson, P.R., Yarur, A., Bellaguarda, E., Corsello, P.,\nGaetano, J.N., Kinnucan, J., Rao, V.L., Reddy, S., Singh, S., Pekow, J., Rubin, D.T.,\n2018. Vedolizumab in patients with concurrent primary sclerosing cholangitis and\nin\ufb02ammatory bowel disease does not improve liver biochemistry but is safe and\neffective for the bowel disease. Aliment. Pharmacol. Ther. 47 (6), 753\u2013762."}]}, {"question": "28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago\n", "answer": "{\"drug_name\": \"Vedolizumab\", \"advantages\": \"Vedolizumab is a first-line therapy for moderate to severely active ulcerative colitis. It is especially beneficial for patients who have had prior exposure to TNF antagonists. It is also a good choice for this patient due to her history of lymphoma, as Vedolizumab has a lower risk of reactivating latent infections or causing malignancies compared to other biologics.\", \"disadvantages\": \"The main disadvantage of Vedolizumab is that it may take longer to work compared to other biologics. It also requires intravenous administration, which can be inconvenient for some patients.\"}, \n\n{\"drug_name\": \"Ustekinumab\", \"advantages\": \"Ustekinumab can be used if the patient has prior exposure to TNF antagonists. It is also a good choice for this patient due to her history of lymphoma, as Ustekinumab has a lower risk of reactivating latent infections or causing malignancies compared to other biologics.\", \"disadvantages\": \"The main disadvantage of Ustekinumab is that it may not be as effective as other biologics in inducing remission in ulcerative colitis. It also requires subcutaneous administration, which can be inconvenient for some patients.\"}", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "Introduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "needed to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "colitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;\nand (4) outcome: induction of clinical remission (Mayo\nClinic score of \ufffd2 with no individual subscore of >1)"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "clinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}]}, {"question": "36 year old woman with moderate ulcerative colitis and multiple sclerosis", "answer": "I don't know.", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "Introduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 5, "text": "Table 1. Overall, the median average age of patients was\n41 years (interquartile range, 40\u201342 y), and 60%\n(interquartile range, 56%\u201363%) were men. The median\ndisease duration was 6.7 years (interquartile range,\n6.0\u20137.8 y), and 49% (interquartile range, 46%\u201355%) of\npatients had extensive colitis. A median of 40% (inter-\nquartile range, 30%\u201350%) of patients were treated with\nconcomitant immunomodulators, and 51% (interquartile\nrange, 45%\u201357%) were on corticosteroids at baseline.\nPatients across all trials and treatment arms were com-\nparable in terms of baseline prognostic variables, inclu-\nsion/exclusion\ncriteria,\nand\nco-interventions.\nAll\noutcomes were assessed uniformly based on the stan-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "clinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "patients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials"}]}]}